Black checkmark with a sparkle and a curved line underneath on a white background.
Company

Jasper Therapeutics, Inc.

Ticker
JSPR
Sector
Industry
Report date
November 16, 2026
Valye AI Score

100

Very high visibility
Recent developments
Recent developments summary

Recent developments include completion of the Kira Pharmaceuticals merger, securing $132 million in financing, advancing clinical milestones for briquilimab and other pipeline candidates, and corporate actions such as a reverse stock split and warrant purchase offer.

Recent developments:
  • Jasper Therapeutics completed the merger with Kira Pharmaceuticals in July 2026, expanding its pipeline and focusing on multiple clinical milestones through 2027 [N5].
  • The company secured $132 million in financing in August 2026 to advance its post-Kira clinical pipeline [N4].
  • Jasper Therapeutics announced nearing data readout for IgA Nephropathy and plans a FSGS study in 2027 [N3].
  • The company announced a 1-for-30 reverse stock split in November 2026 [N1].
  • Jasper Therapeutics announced results of a warrant purchase offer in November 2026 [N1].
  • Positive clinical results for briquilimab in allergic asthma Phase 1b study were reported in December 2025 [N7].
  • The company hosted a webinar to present BEACON and ETESIAN study results in December 2025 [N8].
  • RBC Capital maintained a Sector Perform recommendation on Jasper Therapeutics in November 2025 [N8].
Overview

Jasper Therapeutics, Inc. is a clinical-stage biotechnology company specializing in therapeutics for mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU), and asthma. Its lead product candidate, briquilimab, is a humanized monoclonal antibody that blocks the SCF/KIT pathway critical for mast cell survival, aiming to deplete mast cells and alleviate disease symptoms. The company has conducted multiple clinical trials including the BEACON study in CSU, SPOTLIGHT study in CIndU, an Open Label Extension study, and the ETESIAN study in asthma, reporting positive efficacy and safety data. In 2026, Jasper completed a merger with Kira Pharmaceuticals, expanding its pipeline to include KP104 and KP701, targeting complement pathways and autoantibody-mediated disorders respectively. The company has secured significant financing to support its clinical development programs. Jasper operates under exclusive license agreements with Amgen and Stanford University for briquilimab. Despite promising clinical progress, the company has a history of net losses and negative cash flows, with liquidity supported by recent financing and cash reserves as of September 2026.

Executive summary

Jasper Therapeutics, Inc. is a clinical-stage biotech company focused on mast cell driven diseases, developing briquilimab, a monoclonal antibody targeting the SCF/KIT pathway to deplete mast cells. The company has reported positive clinical data in CSU, CIndU, and asthma, with ongoing studies and an expanded pipeline following its 2026 merger with Kira Pharmaceuticals. As of September 30, 2026, Jasper held $135.3 million in cash and equivalents, with a current ratio of 10.59. The company has incurred significant net losses and negative cash flows, raising substantial doubt about its ability to continue as a going concern. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.

Scenarios for JSPR

Bull case model:

Jasper Therapeutics has demonstrated positive clinical data for briquilimab in multiple mast cell driven diseases, including CSU, CIndU, and asthma, with rapid onset of efficacy and favorable safety profiles. The company's strategic merger with Kira Pharmaceuticals expands its pipeline into complementary therapeutic areas, supported by significant financing to advance clinical programs. The unique mechanism of action targeting the SCF/KIT pathway and exclusive licensing agreements provide a foundation for potential future commercial opportunities. Continued clinical progress and successful integration of acquired assets could enhance the company's position in immunologically-driven disorders.

Bear case model:

Jasper Therapeutics faces substantial risks including its history of significant net losses and negative cash flows, raising doubts about its ability to continue as a going concern. The company is pre-commercial with no approved products and depends heavily on successful clinical development and regulatory approvals, which are inherently uncertain. Integration challenges following the merger with Kira Pharmaceuticals may disrupt operations and delay pipeline advancement. Additionally, stockholder approval delays related to convertible preferred stock and the risk that acquired product candidates may not advance could materially harm business prospects. The company requires additional capital to sustain operations, exposing it to financing risks.

Moat:

Jasper Therapeutics' moat is centered on its proprietary monoclonal antibody briquilimab, which uniquely targets the SCF/KIT pathway to deplete mast cells, a novel mechanism in treating mast cell driven diseases. The company holds exclusive licensing agreements with Amgen and Stanford University, providing global rights to develop and commercialize briquilimab. Its clinical-stage pipeline is supported by positive early clinical data across multiple indications, and the recent merger with Kira Pharmaceuticals broadens its therapeutic portfolio into complement and autoantibody-mediated disorders. The specialized focus on mast cell biology and the integration of acquired assets contribute to a differentiated position in a niche therapeutic area. However, the company remains pre-commercial with no approved products, and its competitive advantage depends on successful clinical development and regulatory approvals.

Risks overview
Risks summary
The most significant risks include financial sustainability concerns due to ongoing losses and cash flow deficits, integration challenges from the recent merger, and uncertainties inherent in clinical development and regulatory approval processes.
Risks details:

• Integration Risks Post-Merger: Challenges in integrating Kira Pharmaceuticals' operations, pipelines, and management could disrupt business, delay clinical programs, and increase expenses.
• Financial Sustainability: Significant net losses and negative operating cash flows raise substantial doubt about the company's ability to continue as a going concern beyond one year from the latest filing date.
• Clinical and Regulatory Uncertainty: Clinical trials may not demonstrate safety or efficacy sufficient for regulatory approval, and early positive data may not predict later-stage results.
• Stockholder Approval Risks: Failure to obtain stockholder approval for conversion of convertible preferred stock could require cash settlements, materially harming financial condition.
• Dependence on Licensing and Partnerships: The company's ability to realize financial benefits depends on partners like Amgen and Mirador Therapeutics, whose performance is outside Jasper's control.

FINAL FORECAST FOR JSPR

Final take one line
Jasper Therapeutics has detailed clinical-stage programs targeting mast cell diseases with an expanded pipeline post-merger, supported by strong liquidity but facing integration and financial sustainability risks.
Final take 12 to 24 month view

Business trends: Continued clinical development of briquilimab in mast cell driven diseases and advancement of newly acquired pipeline candidates post-Kira merger.
Execution milestones: Completion of clinical data readouts for IgAN and FSGS studies, integration of Kira assets, and execution of financing and corporate actions.
Key risks: Integration challenges, ongoing net losses and cash flow deficits, clinical and regulatory uncertainties, and stockholder approval dependencies.

Valye AI Visibility Research Score

Very high visibility

Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).

100
LLM visibility overview
LLM Visibility known facts
  • Jasper Therapeutics is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU), and asthma, with ongoing evaluation of additional mast cell driven indications.
  • The company has discontinued prior programs targeting diseased hemopoietic stem cells and is exclusively focused on mast cell driven diseases.
  • Their lead product candidate is briquilimab, a humanized monoclonal antibody designed to block stem cell factor (SCF) from binding to the CD117 (KIT) receptor on mast and stem cells, aiming to deplete mast cells and provide clinical benefit in mast cell driven diseases.
  • Briquilimab has been studied in multiple clinical trials: the Phase 1b/2a BEACON study in CSU, the Phase 1b/2a SPOTLIGHT study in CIndU, an Open Label Extension (OLE) study for CSU and CIndU, and the Phase 1b ETESIAN study in asthma.
  • BEACON study data showed rapid onset of clinical efficacy with responses as early as 1 week post-dose and complete responses by week 2, with strong efficacy at doses of 180mg or higher and a favorable safety profile characterized by generally transient, low-grade KIT-related adverse events.
  • An investigation into atypical efficacy results in certain BEACON cohorts attributed the anomaly to patient selection criteria at some clinical sites rather than product issues, leading to protocol adjustments for future studies.
  • SPOTLIGHT study in CIndU showed 96% of participants achieving clinical response within 8 weeks and 88% achieving complete response at higher doses, with good tolerability and low-grade KIT-related adverse events.
  • OLE study data indicated durable disease control in CSU and CIndU patients with briquilimab 180mg Q8W dosing, maintaining favorable safety.
  • ETESIAN study in asthma demonstrated proof-of-concept with briquilimab reducing allergen-induced late asthmatic response and inflammatory markers compared to placebo.
  • Jasper Therapeutics has an exclusive license agreement with Amgen for briquilimab development and commercialization worldwide, and a license with Stanford University for use in hematopoietic stem cell transplantation.
  • The company completed a merger with Kira Pharmaceuticals in July 2026, expanding its pipeline to include KP104 (in Phase 2 trials for renal indications and PNH) and KP701 (preclinical candidate for autoantibody-mediated disorders).
  • Post-merger, Jasper faces integration challenges including managing a broader pipeline, hiring expertise, and navigating new regulatory pathways.
  • The company secured $132 million in financing in August 2026 to advance its clinical pipeline post-Kira acquisition.
  • As of September 30, 2026, Jasper reported cash and equivalents of $135.3 million, current assets of $147.3 million, current liabilities of $13.9 million, a current ratio of 10.59, and a cash ratio of 9.97, indicating strong liquidity.
  • For the nine months ended September 30, 2026, Jasper reported revenue of $8 million, net loss of $144.5 million, and basic and diluted EPS of -$10.19 per share.
  • The company has incurred significant net losses and negative operating cash flows since inception, raising substantial doubt about its ability to continue as a going concern beyond one year from the 10-Q filing date.
  • Jasper is advancing briquilimab as a chronic therapy in mast cell driven diseases and is evaluating additional indications and product candidates from its expanded pipeline.
  • The company announced a 1-for-30 reverse stock split in November 2026 and results of a warrant purchase offer.
  • Jasper plans multiple clinical milestones through 2027, including data readouts for IgAN and studies in FSGS.
  • The company has reported positive clinical data for briquilimab in allergic asthma and chronic urticaria indications, and continues to host webinars and present study results.
  • Risks include integration challenges post-merger, need for additional capital, clinical and regulatory uncertainties, potential stockholder approval delays related to convertible preferred stock, and the possibility that acquired product candidates may not advance successfully.
Sources
Sources - Context summary

Generated 2026-11-16

Sources - Earning calls
Sources - Other context
Sources - SEC Filings
  • S1 | 2026-03-30 | 10-K
  • S2 | 2026-11-16 | 10-Q
Sources - News headlines
  • N1 | 2026-11-09 | www.nasdaq.com | Jasper Therapeutics, Inc. Announces Results of Warrant Purchase Offer | https://www.nasdaq.com/articles/jasper-therapeutics-inc-announces-results-warrant-purchase-offer
  • N2 | 2026-11-03 | www.nasdaq.com | Zoetis Gears Up to Report Q3 Earnings: Here's What to Expect | https://www.nasdaq.com/articles/zoetis-gears-report-q3-earnings-heres-what-expect
  • N3 | 2026-10-15 | www.nasdaq.com | Jasper Therapeutics Nears IgAN Data Readout, Plans FSGS Study In 2027 | https://www.nasdaq.com/articles/jasper-therapeutics-nears-igan-data-readout-plans-fsgs-study-2027
  • N4 | 2026-08-14 | www.nasdaq.com | Jasper Therapeutics Secures $132M In Financing; Advances Post-Kira Clinical Pipeline | https://www.nasdaq.com/articles/jasper-therapeutics-secures-132m-financing-advances-post-kira-clinical-pipeline
  • N5 | 2026-07-17 | www.nasdaq.com | Jasper Completes Kira Acquisition, Eyes Multiple Clinical Milestones Through 2027; Stock Down | https://www.nasdaq.com/articles/jasper-completes-kira-acquisition-eyes-multiple-clinical-milestones-through-2027-stock
  • N6 | 2026-05-25 | www.nasdaq.com | AZN, Daiichi's Datroway Wins FDA Nod for Expanded Use in Breast Cancer | https://www.nasdaq.com/articles/azn-daiichis-datroway-wins-fda-nod-expanded-use-breast-cancer
  • N7 | 2025-12-02 | www.nasdaq.com | Jasper Therapeutics Reports Positive Results For Briquilimab In Allergic Asthma Phase 1b Study | https://www.nasdaq.com/articles/jasper-therapeutics-reports-positive-results-briquilimab-allergic-asthma-phase-1b-study
  • N8 | 2025-12-02 | www.nasdaq.com | Jasper Therapeutics To Host Webinar To Present BEACON And ETESIAN Study Results | https://www.nasdaq.com/articles/jasper-therapeutics-host-webinar-present-beacon-and-etesian-study-results
Important legal disclaimer

This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Blue logo with a stylized checkmark and star above the blue text 'VALYE' on a black background.

Generated by Valye SEC Pipeline Engine